Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 with Platinum-Etoposide in First-Line ES-SCLC
NCT05844150Phase 2Active, not recruiting
- Sponsor
- Biotheus
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in small cell lung cancer (SCLC), sponsored by Biotheus. Started Jun 2023; status: active, not recruiting.
02
Drugs
pumitamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05844150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844150.